Basic Information
RNALocate ID: | RLID:11000750 |
RNA Symbol: | hsa-miR-20a-5p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-20a |
RNA ID: | miRBase:MIMAT0000075 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23539611 |
Tissue/Cell Line: | Seminal plasma |
Method: | Microarray |
Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001294 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001295 | Cytoplasm | Cell line (HeLa) | 21695135 |
RLID:01001296 | Cytoplasm | HeLa cells | 23940654 |
RLID:01001297 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001298 | Mitochondrion | Myotube | 27396686 |
RLID:01001299 | Mitochondrion | Skeletal muscle cells | 27563705 |
RLID:01001300 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001301 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001302 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001303 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
RLID:01001304 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11000737 | Exosome | Sera | 24978137 |
RLID:11000738 | Exosome | Human cervical carcinoma cell line (HeLa|SiHa) | 25760330 |
RLID:11000739 | Exosome | Glioblastoma cells | 19011622 |
RLID:11000740 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000741 | Exosome | Breast milk | 22211110 |
RLID:11000742 | Exosome | Brain tissue | 23382797 |
RLID:11000743 | Exosome | Plasma | 23663360 |
RLID:11000744 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000745 | Exosome | Serum | 25349172 |
RLID:11000746 | Exosome | Cerebrospinal fluid | 25420022 |
RLID:11000747 | Extracellular Vesicle | Liposarcoma cell lines (Lipo246|Lipo863|LPS141)|Preadipocytes | 28588009 |
RLID:11000748 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11000749 | Microvesicle | Glioblastoma cells | 19011622 |
RLID:11000751 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000012 | Exosome | B lymphoblastoid cells|Chronic lymphocytic leukemia cells|Endothelial cells|Epithelial cells|Lymphoma tissue|Tongue tissue | |
RLID-D:11000274 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-20a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-27697 |
MNDR | hsa-miR-20a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-27698 |
MNDR | hsa-miR-20a-5p | Colorectal adenocarcinoma | MNDR-E-MI-27699 |
MNDR | hsa-miR-20a-5p | Oral squamous cell carcinoma | MNDR-E-MI-27700 |
MNDR | hsa-miR-20a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-27701 |
MNDR | hsa-miR-20a-5p | Medulloblastoma | MNDR-E-MI-27702 |
MNDR | hsa-miR-20a-5p | B cell lymphoma of malt type | MNDR-E-MI-27703 |
MNDR | hsa-miR-20a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-27704 |
MNDR | hsa-miR-20a-5p | Autism spectrum disorder | MNDR-E-MI-27705 |
MNDR | hsa-miR-20a-5p | Lymphoma | MNDR-E-MI-27706 |
MNDR | hsa-miR-20a-5p | Lymphoma non-hodgkin | MNDR-E-MI-27707 |
MNDR | hsa-miR-20a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-27708 |
MNDR | hsa-miR-20a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-27709 |
MNDR | hsa-miR-20a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-27710 |
MNDR | hsa-miR-20a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-27711 |
MNDR | hsa-miR-20a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-27712 |
MNDR | hsa-miR-20a-5p | Breast cancer luminal | MNDR-E-MI-27713 |
MNDR | hsa-miR-20a-5p | Niemann-pick disease type c | MNDR-E-MI-27714 |
MNDR | hsa-miR-20a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-27715 |
MNDR | hsa-miR-20a-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-27716 |
MNDR | hsa-miR-20a-5p | Dermatomyositis | MNDR-E-MI-27717 |
MNDR | hsa-miR-20a-5p | Prostate cancer | MNDR-E-MI-27718 |
MNDR | hsa-miR-20a-5p | Gastric cancer | MNDR-E-MI-27719 |
MNDR | hsa-miR-20a-5p | Gastric lymphoma | MNDR-E-MI-27720 |
MNDR | hsa-miR-20a-5p | Alzheimer disease | MNDR-E-MI-27721 |
MNDR | hsa-miR-20a-5p | Intracranial aneurysm | MNDR-E-MI-27722 |
MNDR | hsa-miR-20a-5p | Bladder cancer | MNDR-E-MI-27723 |
MNDR | hsa-miR-20a-5p | Esophageal carcinoma | MNDR-E-MI-27724 |
MNDR | hsa-miR-20a-5p | Dysautonomia familial | MNDR-E-MI-27725 |
MNDR | hsa-miR-20a-5p | Primary biliary cirrhosis | MNDR-E-MI-27726 |
MNDR | hsa-miR-20a-5p | Leukemia | MNDR-E-MI-27727 |
MNDR | hsa-miR-20a-5p | Ataxia telangiectasia | MNDR-E-MI-27728 |
MNDR | hsa-miR-20a-5p | Huntington disease | MNDR-E-MI-27729 |
MNDR | hsa-miR-20a-5p | Chorea | MNDR-E-MI-27730 |
MNDR | hsa-miR-20a-5p | Cardiovascular disease | MNDR-E-MI-27731 |
MNDR | hsa-miR-20a-5p | Carotid stenosis | MNDR-E-MI-27732 |
MNDR | hsa-miR-20a-5p | Moyamoya disease | MNDR-E-MI-27733 |
MNDR | hsa-miR-20a-5p | Lung cancer | MNDR-E-MI-27734 |
MNDR | hsa-miR-20a-5p | Down syndrome | MNDR-E-MI-27735 |
MNDR | hsa-miR-20a-5p | Parkinson disease | MNDR-E-MI-27736 |
MNDR | hsa-miR-20a-5p | Niemann-pick disease | MNDR-E-MI-27737 |
MNDR | hsa-miR-20a-5p | Colon carcinoma | MNDR-E-MI-27738 |
MNDR | hsa-miR-20a-5p | Basal-like breast cancer | MNDR-E-MI-27739 |
MNDR | hsa-miR-20a-5p | Squamous cell carcinoma | MNDR-E-MI-27740 |
MNDR | hsa-miR-20a-5p | Thyroid cancer | MNDR-E-MI-27741 |
MNDR | hsa-miR-20a-5p | Pituitary neoplasms | MNDR-E-MI-27742 |
MNDR | hsa-miR-20a-5p | Pancreatic cancer | MNDR-E-MI-27743 |
MNDR | hsa-miR-20a-5p | Melanoma | MNDR-E-MI-27744 |
MNDR | hsa-miR-20a-5p | Lesch-nyhan syndrome | MNDR-E-MI-27745 |
MNDR | hsa-miR-20a-5p | Rectum adenocarcinoma | MNDR-E-MI-27746 |
MNDR | hsa-miR-20a-5p | Nephroblastoma | MNDR-E-MI-27747 |
MNDR | hsa-miR-20a-5p | Colon cancer | MNDR-E-MI-27748 |
MNDR | hsa-miR-20a-5p | Ischemic attack transient | MNDR-E-MI-27749 |
MNDR | hsa-miR-20a-5p | Colon adenocarcinoma | MNDR-E-MI-27750 |
MNDR | hsa-miR-20a-5p | Multiple sclerosis | MNDR-E-MI-27751 |
MNDR | hsa-miR-20a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-27752 |
MNDR | hsa-miR-20a-5p | Ovarian cancer | MNDR-E-MI-27753 |
MNDR | hsa-miR-20a-5p | Prostate adenocarcinoma | MNDR-E-MI-27754 |
MNDR | hsa-miR-20a-5p | Kidney cancer | MNDR-E-MI-27755 |
MNDR | hsa-miR-20a-5p | Endometriosis | MNDR-E-MI-27756 |
MNDR | hsa-miR-20a-5p | Carcinoma ductal breast | MNDR-E-MI-27757 |
MNDR | hsa-miR-20a-5p | Glioblastoma | MNDR-E-MI-27758 |
MNDR | hsa-miR-20a-5p | Astrocytoma | MNDR-E-MI-27759 |
MNDR | hsa-miR-20a-5p | Glioma | MNDR-E-MI-27760 |
MNDR | hsa-miR-20a-5p | Oligodendroglioma | MNDR-E-MI-27761 |
MNDR | hsa-miR-20a-5p | Central nervous system lymphoma | MNDR-E-MI-27762 |
MNDR | hsa-miR-20a-5p | Chordoma | MNDR-E-MI-27763 |
MNDR | hsa-miR-20a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-27764 |
MNDR | hsa-miR-20a-5p | Epilepsy temporal lobe | MNDR-E-MI-27765 |
MNDR | hsa-miR-20a-5p | Osteosarcoma | MNDR-E-MI-27766 |
MNDR | hsa-miR-20a-5p | Liposarcoma | MNDR-E-MI-27767 |
MNDR | hsa-miR-20a-5p | Meningioma | MNDR-E-MI-27768 |
MNDR | hsa-miR-20a-5p | Liver cancer | MNDR-E-MI-27769 |
MNDR | hsa-miR-20a-5p | Uterine cancer | MNDR-E-MI-27770 |
MNDR | hsa-miR-20a-5p | Gastric adenocarcinoma | MNDR-E-MI-27771 |
MNDR | hsa-miR-20a-5p | Pituitary adenoma | MNDR-E-MI-27772 |
MNDR | hsa-miR-20a-5p | Lung squamous cell carcinoma | MNDR-E-MI-27773 |
MNDR | hsa-miR-20a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-27774 |
MNDR | hsa-miR-20a-5p | Lung adenocarcinoma | MNDR-E-MI-27775 |
MNDR | hsa-miR-20a-5p | Adrenocortical carcinoma | MNDR-E-MI-27776 |
MNDR | hsa-miR-20a-5p | Thyroid carcinoma | MNDR-E-MI-27777 |
MNDR | hsa-miR-20a-5p | Ovarian carcinoma | MNDR-E-MI-27778 |
MNDR | hsa-miR-20a-5p | Bladder urothelial carcinoma | MNDR-E-MI-27779 |
MNDR | hsa-miR-20a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-27780 |
MNDR | hsa-miR-20a-5p | Brain stem cancer | MNDR-E-MI-27781 |
MNDR | hsa-miR-20a-5p | Cervical cancer | MNDR-E-MI-27782 |
MNDR | hsa-miR-20a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-27783 |
MNDR | hsa-miR-20a-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-27784 |
MNDR | hsa-miR-20a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-27785 |
MNDR | hsa-miR-20a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-27786 |
MNDR | hsa-miR-20a-5p | Biliary tract cancer | MNDR-E-MI-27787 |
MNDR | hsa-miR-20a-5p | Pancreatic carcinoma | MNDR-E-MI-27788 |
MNDR | hsa-miR-20a-5p | Cholangiocarcinoma | MNDR-E-MI-27789 |
MNDR | hsa-miR-20a-5p | Esophageal cancer | MNDR-E-MI-27790 |
MNDR | hsa-miR-20a-5p | Lung small cell carcinoma | MNDR-E-MI-27791 |
MNDR | hsa-miR-20a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-27792 |
MNDR | hsa-miR-20a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-27793 |
MNDR | hsa-miR-20a-5p | Acute t cell leukemia | MNDR-E-MI-27794 |
MNDR | hsa-miR-20a-5p | Pulmonary hypertension | MNDR-E-MI-27795 |
MNDR | hsa-miR-20a-5p | Adenoma | MNDR-E-MI-27796 |
MNDR | hsa-miR-20a-5p | Breast invasive carcinoma | MNDR-E-MI-27797 |
MNDR | hsa-miR-20a-5p | Early hepatocellular carcinoma | MNDR-E-MI-27798 |
MNDR | hsa-miR-20a-5p | B-cell lymphoma | MNDR-E-MI-27799 |
MNDR | hsa-miR-20a-5p | Rheumatoid arthritis | MNDR-E-MI-27800 |
MNDR | hsa-miR-20a-5p | T-cell leukemia | MNDR-E-MI-27801 |
MNDR | hsa-miR-20a-5p | Retinoblastoma | MNDR-E-MI-27802 |
MNDR | hsa-miR-20a-5p | Neuroblastoma | MNDR-E-MI-27803 |
MNDR | hsa-miR-20a-5p | Chronic myeloid leukemia | MNDR-E-MI-27804 |
MNDR | hsa-miR-20a-5p | Hodgkin disease | MNDR-E-MI-27805 |
MNDR | hsa-miR-20a-5p | Burkitt lymphoma | MNDR-E-MI-27806 |
MNDR | hsa-miR-20a-5p | Lymphosarcoma | MNDR-E-MI-27807 |
MNDR | hsa-miR-20a-5p | Neuromyelitis optica | MNDR-E-MI-27808 |
MNDR | hsa-miR-20a-5p | Psoriasis | MNDR-E-MI-27809 |
MNDR | hsa-miR-20a-5p | Acute myelogenous leukemia | MNDR-E-MI-27810 |
MNDR | hsa-miR-20a-5p | Colorectal cancer | MNDR-E-MI-27811 |
MNDR | hsa-miR-20a-5p | Multiple myeloma | MNDR-E-MI-27812 |
MNDR | hsa-miR-20a-5p | Acute lymphocytic leukemia | MNDR-E-MI-27813 |
MNDR | hsa-miR-20a-5p | Uterine cervical neoplasms | MNDR-E-MI-27814 |
MNDR | hsa-miR-20a-5p | Ependymoma | MNDR-E-MI-27815 |
MNDR | hsa-miR-20a-5p | Nasopharyngeal cancer | MNDR-E-MI-27816 |
MNDR | hsa-miR-20a-5p | Prostatic neoplasms | MNDR-E-MI-27817 |
MNDR | hsa-miR-20a-5p | Pseudorabies | MNDR-E-MI-27818 |
MNDR | hsa-miR-20a-5p | Arsenic poisoning | MNDR-E-MI-27819 |
MNDR | hsa-miR-20a-5p | Stroke lacunar | MNDR-E-MI-27820 |
MNDR | hsa-miR-20a-5p | Duke C | MNDR-E-MI-27821 |
MNDR | hsa-miR-20a-5p | High grade dysplastic nodule | MNDR-E-MI-27822 |
MNDR | hsa-miR-20a-5p | Tubulovillous adenoma | MNDR-E-MI-27823 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABL2 | Homo sapiens | RR00027165 |
TOP